Search Results

You are looking at 1 - 4 of 4 items for :

  • By Author: Edwards, Michael S. B. x
  • By Author: Cheshier, Samuel H. x
Clear All
Restricted access

Jennifer L. Quon, Lily H. Kim, Peter H. Hwang, Zara M. Patel, Gerald A. Grant, Samuel H. Cheshier and Michael S. B. Edwards

/51 (3.9%) 0/14 (0%) 1/22 (4.5%) 1/15 (6.7%)  Graft migration 2/51 (3.9%) 0/14 (0%) 2/22 (9.1%) 0/15 (0%)  Death 1/51 (2.0%) 0/14 (0%) 1/22 (4.5%) 0/15 (0%) Median follow-up time, mos 46 (1–120) 18.5 (1–64) 57 (21–114) 46 (22–120) No. of recurrences 5/32 (15.6%) 2/11 (18.2%) 3/16 (18.8%) 0/5 (0%) No. of reops 9/51 (17.6%) 2/14 (14.3%) 6/22 (27.3%) 1/15 (6.7%) Adjuvant therapy, any 32/42 (76.2%) 9/12 (75%) 14/16 (87.5%) 9/14 (64.3%)  Hormonal therapy 29/42 (69.0%) 9/12 (75%) 12/16 (75%) 8/14 (57.1%)  Radiation therapy 12/42 (28.6%) 2/12 (16.7%) 4/16 (25%) 6/14 (42

Restricted access

Robert M. Lober, Raphael Guzman, Samuel H. Cheshier, Douglas R. Fredrick, Michael S. B. Edwards and Kristen W. Yeom

gliomatosis in NF1-associated tumors by using MRI-DT imaging. Further studies will be required to determine if the various tractography fiber arrangements, for example, as seen with the prechiasmatic lesions in Fig. 2 , correspond to these known histopathological variants. Our preliminary data as of this writing, previously presented only in abstract form (see end matter), suggest that diffusion characteristics may differentiate indolent lesions from those more likely to progress and require therapy, whereas previous imaging modalities have failed. At present, it remains

Restricted access

Derek Yecies, Katie Shpanskaya, Rashad Jabarkheel, Maryam Maleki, Lisa Bruckert, Samuel H. Cheshier, David Hong, Michael S. B. Edwards, Gerald A. Grant and Kristen W. Yeom

understanding of the pathophysiology of PFS will hopefully lead to further investigations into treatments for PFS that may be aided by imaging biomarkers such as ASL. To date, there have been several reports of resolution of PFS with pharmacological therapy with drugs such as midazolam, zolpidem, and bromocriptine. 1 , 29 , 39 While it remains to be seen if these proposed therapies will have generalizable efficacy for PFS, the need to explore treatments for this condition is highlighted by the numerous papers demonstrating that children with PFS have significantly poorer

Restricted access

Tej D. Azad, Arjun V. Pendharkar, James Pan, Yuhao Huang, Amy Li, Rogelio Esparza, Swapnil Mehta, Ian D. Connolly, Anand Veeravagu, Cynthia J. Campen, Samuel H. Cheshier, Michael S. B. Edwards, Paul G. Fisher and Gerald A. Grant

adult natural history and outcome variables could not be distinguished, and studies in which intramedullary location of the tumor could not be confirmed in the report. Data Extraction From the 29 published studies, we extracted the study type, sample size, patient demographics, extent of resection, adjuvant therapy, and outcome measures. We collected data on the following outcomes: OS and recurrence rate. These data were either directly taken from the studies when reported or calculated from raw data published in the paper. Data Synthesis Using data from studies that